Company Profile

Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Employees

103

Sector

Biotechnology & Medical Research

More about the company

24-01-23	Akouos, Inc. Announces Positive Initial Clinical Results from the Phase 1/2 AK-OTOF-101 Study	CI
22-12-01	Akouos, Inc. Announces Executive and Board Changes	CI
22-12-01	Lilly Wraps Up Acquisition of Akouos	MT
22-12-01	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index	CI
22-11-30	Eli Lilly and Company completed the acquisition of Akouos, Inc. from a group of shareholders.	CI
22-11-30	Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing	MT
22-11-30	Akouos, Inc.(NasdaqGS:AKUS) dropped from S&P TMI Index	CI
22-11-29	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index	CI
22-11-14	Akouos Q3 Loss Narrows	MT
22-11-14	Akouos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-10-19	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
22-10-19	William Blair Downgrades Akouos to Market Perform From Outperform	MT
22-10-18	Health Care Up Amid Earnings, Deals -- Health Care Roundup	DJ

22-10-19	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
22-10-19	William Blair Downgrades Akouos to Market Perform From Outperform	MT
22-10-18	HC Wainwright Downgrades Akouos to Neutral from Buy	MT
22-09-29	William Blair Starts Akouos at Outperform	MT
22-05-18	Piper Sandler Adjusts Akouos' Price Target to $18 From $40, Reiterates Overweight Rating	MT

22-12-01	AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22-11-30	Lilly and Akouos Announce Expiration of Akouos Tender Offer	PR
22-11-14	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-11-14	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
22-11-14	Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights	AQ

22-12-01	Eli Lilly : a finalisé l'acquisition d'Akouos
22-11-30	Eli Lilly : vers l'acquisition de 81.1% des actions d'Akouos
22-10-18	Wall Street sluit hoger
22-10-18	Wall Street houdt winst vast
22-10-18	MÄRKTE USA/Börsen setzen Erholung fort

Manager	Title	Age	Since
Emmanuel J. Simons CEO	Chief Executive Officer	43	2015-12-31
Jean Phillips CTO	Chief Tech/Sci/R&D Officer	-	-
Aaron Tward CTO	Chief Tech/Sci/R&D Officer	-	2022-03-09

AKOUOS Stock

Stocks

AKUS

US00973J1016

Biotechnology & Medical Research

Latest news: AKOUOS

Analysts' recommendations: AKOUOS

Press Releases: AKOUOS

News in other languages: AKOUOS

Quotes and Performance

Managers and Directors: AKOUOS

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/1/22	Sona Saira Ramasastry	Issuer sale	Director	16,000	0.0433%
12/1/22	Vicki Sato	Issuer sale	Director	55,030	0.1489%
12/1/22	Sachiyo Minegishi	Issuer sale	Chief Financial Officer	150,000	0.4060%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKOUOS	+1.06%	+0.91%	-	-	491M
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+51.24%	+99.26%	72.26B
ARGENX SE	+1.25%	-3.01%	+37.83%	+87.66%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+35.69%	+23.40%	27.73B
INSMED INCORPORATED	-3.06%	-1.81%	-14.01%	+357.24%	25.74B
BIONTECH SE	-0.75%	+2.56%	+0.45%	-3.28%	24.75B
GENMAB A/S	+0.40%	+0.75%	+23.72%	-11.33%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+326.97%	15.06B
EXELIXIS, INC.	+0.36%	-0.34%	+48.98%	+167.40%	14.42B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-3.95%	+512.06%	14.23B
Average	-0.34%	+0.44%	+36.69%	+173.26%	30.57B
Weighted average by Cap.	-0.76%	+0.31%	+36.44%	+133.04%